Familial Nasopharyngeal Carcinoma 6

Concurrent Chemotherapy-Enhanced Radiation: Trials and Conclusions 181Willett CG, Boucher Y, di Tomaso E, et al (2004) Direct evidencethat the VEGF-specific antibody bevacizumab has antivasculareffects in human rectal cancer. Nat Med 10(2): 145–147Wodinsky I, Swiniarski J, Kensler CJ, et al (1974) Combinationradiotherapy and chemotherapy for P388 lymphocytic leukemiain vivo. Cancer Chemother Rep 2 4(1):73–97Wu RR, Wu SX, Zhao C, et al (2007) [Phase II clinical trial of h-R3combined radiotherapy for locoregionally advanced nasopharyngealcarcinoma]. Ai Zheng 26(8):874–879 [Chinese]Yang AK, Liu TR, Guo X, et al (2008) [Concurrent chemoradiotherapyversus radiotherapy alone for locoregionallyadvanced nasopharyngeal carcinoma: a meta-analysis].Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 43(3):218–223 [Chinese]Yau TK, Lee AW, Wong DH, et al (2006) Treatment of stageIV(A–B) nasopharyngeal carcinoma by induction-concurrentchemoradiotherapy and accelerated fractionation:impact of chemotherapy schemes. Int J Radiat Oncol BiolPhys 66(4):1004–1010Zák M, Drobník J (1971) Effect of cis-dichlorodiamine platinum(II) on the post-irradiation lethality in mice afterirradiation with X-rays. Strahlentherapie 142(1):112–115Zhang L, Zhao C, Peng PJ, et al (2005) Phase III study comparingstandard radiotherapy with or without weekly oxaliplatinin treatment of locoregionally advanced nasopharyn gealcarcinoma: preliminary results. J Clin Oncol 23(33):8461–8468